Physician

Michelle A Levy, M.D.

According to 2025 Medicare claims, Michelle Levy, M.D. (NPI: 1851667596) practices hematology/oncology in the Denver-Aurora-Centennial, CO market, with the plurality of this provider's patient population coming from Arapahoe, CO. This provider's primary affiliated billing organization is ROCKY MOUNTAIN CANCER CENTERS LLP (NPI: 1518941186; TIN: 841457488) and primary practice location at 80218-1237.

Levy's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 634 traditional Medicare patients, billed 119,640 HCPCS/CPT codes, and received $3,595,598 in Medicare payments. The top billing code was 78815 (Nuclear medicine study from skull base to mid-thigh with ct scan). Part D data shows 1,114 prescription claims across 123 beneficiaries totaling $3,019,213 in drug costs, led by Lenalidomide (Lenalidomide). Open Payments data shows 1 records totaling $16. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,007,931 and ending at $3,595,598. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $738 to $3,019,213. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	218	34,087	$1,007,931
2019	517	121,028	$3,689,945
2020	467	120,334	$2,409,587
2021	561	105,412	$2,907,799
2022	610	92,962	$2,775,865
2023	494	73,550	$1,978,432
2024	634	119,640	$3,595,598

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	12	25	$738
2016	16	24	$572
2017	14	35	$3,723
2018	24	83	$44,211
2019	60	432	$639,494
2020	61	589	$1,303,431
2021	85	698	$2,164,589
2022	105	919	$2,589,104
2023	111	1,032	$2,590,271
2024	123	1,114	$3,019,213

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
78815	Nuclear medicine study from skull base to mid-thigh with ct scan	176	192	$1,249
A9552	Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	147	161	$74
80053	Blood test, comprehensive group of blood chemicals	154	646	$10
36415	Insertion of needle into vein for collection of blood sample	148	503	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	147	659	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	48	1,337	$596,765
Brukinsa	Zanubrutinib	35	1,050	$418,290
Jakafi	Ruxolitinib Phosphate	21	630	$334,266
Venclexta	Venetoclax	32	867	$254,433
Ninlaro	Ixazomib Citrate	15	420	$197,549

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$16	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Michelle A. Levy, M.D.?

Tedicare shows public-source Medicare data for Michelle A. Levy, M.D. (NPI 1851667596), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Michelle A. Levy, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Michelle A. Levy, M.D.?

Michelle A. Levy, M.D. is linked to ROCKY MOUNTAIN CANCER CENTERS LLP (billing NPI 1518941186) in the available physician profile data.

Does Michelle A. Levy, M.D. have Open Payments data?

Michelle A. Levy, M.D. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.